Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

This study has been completed.
Sponsor:
Collaborator:
Department of Health, United Kingdom
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00159250
First received: September 8, 2005
Last updated: February 22, 2010
Last verified: February 2010
  Purpose

Duchenne muscular dystrophy (DMD), a fatal muscle degenerative disorder, arises from mutations in the dystrophin gene. Antisense therapy with the use of antisense oligonucleotides (AON) has the potential to restore effectively the production of dystrophin, the defective protein, in >70% of DMD. This could result in increased life expectancy through improved muscle survival and function. Recent scientific research has demonstrated the potential of this technique to skip mutated dystrophin exons, restore the reading frame and generate functional dystrophin protein. Having demonstrated proof-of-principle in human cell culture and animal model studies, we now intend to determine efficacy and safety of this approach to induce dystrophin exon skipping in children with DMD.

The specific aim of this phase I/II study is to assess efficacy (dystrophin production) and safety of intramuscular administered morpholino oligomer directed against exon 51 (AVI-4658 PMO). We are performing parallel preclinical studies to develop methods of systemic delivery that will be necessary for future phase II/III clinical studies.


Condition Intervention Phase
Duchenne Muscular Dystrophy
Drug: AVI-4658 (PMO)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • safety [ Time Frame: days 1, 3, 14-28, 30, 60, 120 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Efficacy of induced skipping of exon 51 in the treated EDB muscle, in at least two of the three subjects per group. [ Time Frame: 3 - 4 weeks ] [ Designated as safety issue: Yes ]
  • Restoration of dystrophin protein expression both by immunocytochemistry and Western blot analysis [ Time Frame: 3-4 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 7
Study Start Date: October 2007
Study Completion Date: March 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: AVI-4658 (PMO)
    morpholino antisense oligonucleotide
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   10 Years to 17 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is male ≥ 10 years and ≤ 17 years of age at the time of study drug administration.
  2. Subject has clinical diagnosis compatible with Duchenne's Muscular Dystrophy (DMD) and evidence of mutational and dystrophin defects from muscle biopsy consistent with DMD (out-of frame deletions, absent dystrophin).Eligible deletions are those that can be rescued by the skipping of exon 51 [45-50; 47-50; 48-50; 49-50; 50; 52; 52-63].
  3. Subject has had a muscle biopsy analysed, showing <5% revertant fibres present. Biopsy may be collected at the time of DMD diagnosis or as part of protocol screening procedures.
  4. Subject is unable to ambulate or stand independently.
  5. Subject has Stage 1 to 3 EDB muscle preservation determined by MRI.
  6. Subject has a forced vital capacity ≥ 25% confirmed within 3 months from Day One.
  7. Subject has mean oxygen saturation monitoring > 94% in overnight domiciliary overnight sleep study within 3 months of Day One.
  8. Subject has the ability to comply with all study evaluations and return for all study.
  9. Subject and parent have psychiatric adjustments, adequately supportive psychosocial circumstances and a full understanding of study aims process and likely outcomes.

Exclusion Criteria:

  1. Subject has had external digitorum brevis (EDB) muscle removed.
  2. Subject has Stage 4 EDB muscle preservation determined by MRI.
  3. Subject has a left ventricular shortening fraction of < 25% and/or an ejection fraction of < 35% by echocardiography at visit one or within three months of visit one.
  4. Subject has evidence of nocturnal hypoventilation (mean oxygen saturation at night of ≤ 94%) confirmed via overnight sleep study at Visit One (as screening procedure) or within 3 months of Visit One by overnight sleep study.
  5. Subject has severe respiratory insufficiency defined by the need for invasive or non-invasive mechanical ventilation (does not include nocturnal ventilatory support).
  6. Subject has severe cognitive dysfunction rendering them unable to understand and collaborate with study protocol.
  7. Subject has immune deficiency or autoimmune disease.
  8. Subject has a known bleeding disorder or has received chronic anticoagulant treatment within three months of study entry.
  9. Subject has received pharmacologic treatment, apart from corticosteroids, that might affect muscle strength or function within 8 weeks of study entry (viz.,anabolic steroids, creatine protein supplementation, albuterol or other beta agonists).
  10. Subject has had surgery within 3 months of study entry or planned for anytime during study.
  11. Subject has active significant illness at time of study entry.
  12. Subject has is unable to undergo MRI testing (viz., has metal implants).
  13. Subject or parent has active psychiatric disorder, has adverse psychosocial circumstances, recent significant emotional loss, history of depressive or anxiety disorders that might interfere with protocol completion or compliance.
  14. Subject has any known allergies to products likely to be used in the study (viz.,antiseptics, anaesthetics).
  15. Subject has used any experimental treatments or has participated in any clinical trial within 4 weeks of study entry.
  16. Subject has used intranasal, inhaled or topical steroids for a condition other than muscular dystrophy within 1 weeks of study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159250

Locations
United Kingdom
Dubowitz Neuromuscular Centre, Hammersmith Hospital and Clinical Trails Unit, St Mary's Hospital
London, United Kingdom, W12 0HS
Sponsors and Collaborators
Imperial College London
Department of Health, United Kingdom
Investigators
Principal Investigator: Francesco Muntoni, FRCPCH Dubowitz neuromuscular Centre, Imperial College, London
Study Director: Kate Bushby, MRCP Institute of Human Genetics, University of Newcastle upon Tyne
Study Director: Volker Straub, FRCPCH Institute of Human Genetics, University of Newcastle upon Tyne
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Mr Gary Roper/Manager Clinical Research Governance Organisation, Imperial College London
ClinicalTrials.gov Identifier: NCT00159250     History of Changes
Other Study ID Numbers: 05/MRE12/32
Study First Received: September 8, 2005
Last Updated: February 22, 2010
Health Authority: United Kingdom: Department of Health

Keywords provided by Imperial College London:
Duchenne muscular dystrophy;
antisense oligonucleotides;
gene restoration;
deletion

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked

ClinicalTrials.gov processed this record on October 19, 2014